Asia Pacific RNAi Therapeutics Market

Market Introduction

RNA interference (RNAi) is a vital biological process in which RNA molecules inhibit gene expression or translation, by neutralizing targeted mRNA molecules. RNAi is an essential research tool in cell culture and living organisms because synthetic dsRNA introduced into cells can induce the suppression of specific genes of interest. RNAi may be used for large-scale screens that orderly shutdown each gene in the cell, which can help to know the components necessary for a particular cellular event such as cell division. The pathway is also used as a practical tool in medicine, biotechnology, and insecticides.

Asia Pacific RNAi Therapeutics Strategic Insights

Strategic insights for the Asia Pacific RNAi Therapeutics provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Asia Pacific RNAi Therapeutics Report Scope

Asia Pacific RNAi Therapeutics Regional Insights

The geographic scope of the Asia Pacific RNAi Therapeutics refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

The Asia Pacific RNAi therapeutics market is expected to reach US$ 218.64 million by 2027 from US$ 107.63 million in 2019. The market is anticipated to grow at a CAGR of 9.3% during 2019–2027. The growth of the market is attributed to factors such as growing investments in RNAi therapies and rising prevalence of infectious diseases & chronic conditions. However, high cost of RNAi therapy development is expected to restrain the growth of the market to a certain extent during the forecast period.

Key Market Segments

In terms of molecule type, the small interfering RNAs (siRNA) segment accounted for larger share of the Asia Pacific RNAi therapeutics market in 2019. Based on route of administration, the pulmonary delivery segment held the largest share of the Asia Pacific RNAi therapeutics market in 2019. In terms of application, the oncology segment accounted for the largest share of the market in 2019. Based on end user, the research and academic laboratories segment held the largest share of the Asia Pacific RNAi therapeutics market in 2019.

Major Sources and Companies Listed

Major primary and secondary sources associated with the Asia Pacific RNAi therapeutics market report are the World Health Organization (WHO), Chinese Center for Disease Control and Prevention, and World Population Prospects, among others.

Reasons to buy report

• It provides understanding of the Asia Pacific RNAi therapeutics market landscape and identifies RNAi therapeutics market segments that are most likely to guarantee a strong return
• It guides to stay ahead of the race by comprehending the ever-changing competitive landscape for the Asia Pacific RNAi therapeutics market
• It helps efficiently plan merger and acquisition and partnership deals in the RNAi therapeutics market by identifying market segments with the most promising probable sales
• It facilitates knowledgeable business decision-making through perceptive and comprehensive analysis of various segments pertaining to the Asia Pacific RNAi therapeutics market.
• It provides revenue forecast of the market based on various segments for the period from 2019 to 2027

ASIA PACIFIC RNAI THERAPEUTICS MARKET SEGMENTATION

By Molecule Type

• Small Interfering RNAs (siRNA)
• MicroRNA (miRNA)

By Route of Administration

• Pulmonary Delivery
• Intravenous Injections
• Intradermal Injections
• Intraperitoneal Injections
• Others

By Application

• Oncology
• Cardiovascular
• Respiratory Disorders
• Renal Diseases
• Genetic Disorders
• Neurodegenerative Disorders
• Infectious Diseases
• Others

By End User

• Research and Academic Laboratories
• Hospitals
• Diagnostic Laboratories

By Country

• Japan
• China
• India
• South Korea
• Australia

Company Profiles

• Benitec Biopharma
• Olix Pharmaceuticals, Inc.
• GlaxoSmithKline plc
• Alnylam Pharmaceuticals, Inc.
• Arrowhead Pharmaceuticals, Inc.